PF-114, a Novel Inhibitor of Bcr-Abl Chimeric Tyrosine Kinase, Attenuates Intracellular CrkL Phosphorylation and Kills Chronic Myeloid Leukemia Cells
Background & Aims. The chimeric tyrosine kinase Bcr-Abl triggers malignant transformation of myeloid cells via phosphorylation of a number of substrates including the CrkL adaptor protein. Pharmacological inhibition of Bcr-Abl mediated signaling is a major strategy in treatment of patients with...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Practical Medicine Publishing House
2016-01-01
|
| Series: | Клиническая онкогематология |
| Subjects: | |
| Online Access: | http://bloodjournal.ru/en/pf-114-a-novel-inhibitor-of-bcr-abl-chimeric-tyrosine-kinase-attenuates-intracellular-crkl-phosphorylation-and-kills-chronic-myeloid-leukemia-cells/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850248929082343424 |
|---|---|
| author | ES Kolotova VV Tatarskii AA Zeifman OV Stroganov VS Stroilov IYu Titov FN Novikov AA Kalinina GG Chilov AA Shtil’ |
| author_facet | ES Kolotova VV Tatarskii AA Zeifman OV Stroganov VS Stroilov IYu Titov FN Novikov AA Kalinina GG Chilov AA Shtil’ |
| author_sort | ES Kolotova |
| collection | DOAJ |
| description | Background & Aims. The chimeric tyrosine kinase Bcr-Abl triggers malignant transformation of myeloid cells via phosphorylation of a number of substrates including the CrkL adaptor protein. Pharmacological inhibition of Bcr-Abl mediated signaling is a major strategy in treatment of patients with chronic myeloid leukemia (CML). A new specific Bcr-Abl inhibitor (PF-114) was designed using a molecular modeling approach. The paper defines the cytotoxicity of PF-114 against CML cells and its effect on the CrkL phosphorylation.
Methods. The cytotoxicity was determined using the MTT assay. The total intracellular CrKL pool (phosphorylated and non-phosphorylated forms) was determined by means of flow cytometry.
Results. Exposure of Bcr-Abl-positive, K562 cell line to PF-114 blocked intracellular CrkL phosphorylation and caused cell death. In contrast, virtually no phosphorylated CrkL was detectable in Bcr-Abl-negative HL60, U937 and Jurkat leukemia cell lines.
Conclusion. Absence of phosphorylation in Bcr-Abl-negative cells (HL60, U937 and Jurkat) and death of HL60 cells under the effect of PF-114 at concentrations exceeding those required to kill K562 cells supports the emergence of PF-114 as a promising drug candidate for CML. |
| format | Article |
| id | doaj-art-97b83956983546b4abd133eb6e2d4a9b |
| institution | OA Journals |
| issn | 1997-6933 2500-2139 |
| language | Russian |
| publishDate | 2016-01-01 |
| publisher | Practical Medicine Publishing House |
| record_format | Article |
| series | Клиническая онкогематология |
| spelling | doaj-art-97b83956983546b4abd133eb6e2d4a9b2025-08-20T01:58:35ZrusPractical Medicine Publishing HouseКлиническая онкогематология1997-69332500-21392016-01-01911510.21320/2500-2139-2016-9-1-1-5PF-114, a Novel Inhibitor of Bcr-Abl Chimeric Tyrosine Kinase, Attenuates Intracellular CrkL Phosphorylation and Kills Chronic Myeloid Leukemia CellsES Kolotova0VV Tatarskii1AA Zeifman2OV Stroganov3VS Stroilov4IYu Titov5FN Novikov6AA Kalinina7GG Chilov8AA Shtil’9N.N. Blokhin Russian Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478N.N. Blokhin Russian Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478N.D. Zelinskii Institute of Organic Chemistry, 47 Leninskii pr-t, Moscow, Russian Federation, 119991; Fusion Pharma, 18 bld. 2 Generala Dorokhova str., Moscow, Russian Federation, 119530N.D. Zelinskii Institute of Organic Chemistry, 47 Leninskii pr-t, Moscow, Russian Federation, 119991; Fusion Pharma, 18 bld. 2 Generala Dorokhova str., Moscow, Russian Federation, 119530N.D. Zelinskii Institute of Organic Chemistry, 47 Leninskii pr-t, Moscow, Russian Federation, 119991; Fusion Pharma, 18 bld. 2 Generala Dorokhova str., Moscow, Russian Federation, 119530N.D. Zelinskii Institute of Organic Chemistry, 47 Leninskii pr-t, Moscow, Russian Federation, 119991;Fusion Pharma, 18 bld. 2 Generala Dorokhova str., Moscow, Russian Federation, 119530N.D. Zelinskii Institute of Organic Chemistry, 47 Leninskii pr-t, Moscow, Russian Federation, 119991; Fusion Pharma, 18 bld. 2 Generala Dorokhova str., Moscow, Russian Federation, 119530N.N. Blokhin Russian Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478N.D. Zelinskii Institute of Organic Chemistry, 47 Leninskii pr-t, Moscow, Russian Federation, 119991; Fusion Pharma, 18 bld. 2 Generala Dorokhova str., Moscow, Russian Federation, 119530N.N. Blokhin Russian Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478Background & Aims. The chimeric tyrosine kinase Bcr-Abl triggers malignant transformation of myeloid cells via phosphorylation of a number of substrates including the CrkL adaptor protein. Pharmacological inhibition of Bcr-Abl mediated signaling is a major strategy in treatment of patients with chronic myeloid leukemia (CML). A new specific Bcr-Abl inhibitor (PF-114) was designed using a molecular modeling approach. The paper defines the cytotoxicity of PF-114 against CML cells and its effect on the CrkL phosphorylation. Methods. The cytotoxicity was determined using the MTT assay. The total intracellular CrKL pool (phosphorylated and non-phosphorylated forms) was determined by means of flow cytometry. Results. Exposure of Bcr-Abl-positive, K562 cell line to PF-114 blocked intracellular CrkL phosphorylation and caused cell death. In contrast, virtually no phosphorylated CrkL was detectable in Bcr-Abl-negative HL60, U937 and Jurkat leukemia cell lines. Conclusion. Absence of phosphorylation in Bcr-Abl-negative cells (HL60, U937 and Jurkat) and death of HL60 cells under the effect of PF-114 at concentrations exceeding those required to kill K562 cells supports the emergence of PF-114 as a promising drug candidate for CML.http://bloodjournal.ru/en/pf-114-a-novel-inhibitor-of-bcr-abl-chimeric-tyrosine-kinase-attenuates-intracellular-crkl-phosphorylation-and-kills-chronic-myeloid-leukemia-cells/chronic myeloid leukemiaBcr-Abl tyrosine kinaseprotein phosphorylationflow cytometrycytotoxicity |
| spellingShingle | ES Kolotova VV Tatarskii AA Zeifman OV Stroganov VS Stroilov IYu Titov FN Novikov AA Kalinina GG Chilov AA Shtil’ PF-114, a Novel Inhibitor of Bcr-Abl Chimeric Tyrosine Kinase, Attenuates Intracellular CrkL Phosphorylation and Kills Chronic Myeloid Leukemia Cells Клиническая онкогематология chronic myeloid leukemia Bcr-Abl tyrosine kinase protein phosphorylation flow cytometry cytotoxicity |
| title | PF-114, a Novel Inhibitor of Bcr-Abl Chimeric Tyrosine Kinase, Attenuates Intracellular CrkL Phosphorylation and Kills Chronic Myeloid Leukemia Cells |
| title_full | PF-114, a Novel Inhibitor of Bcr-Abl Chimeric Tyrosine Kinase, Attenuates Intracellular CrkL Phosphorylation and Kills Chronic Myeloid Leukemia Cells |
| title_fullStr | PF-114, a Novel Inhibitor of Bcr-Abl Chimeric Tyrosine Kinase, Attenuates Intracellular CrkL Phosphorylation and Kills Chronic Myeloid Leukemia Cells |
| title_full_unstemmed | PF-114, a Novel Inhibitor of Bcr-Abl Chimeric Tyrosine Kinase, Attenuates Intracellular CrkL Phosphorylation and Kills Chronic Myeloid Leukemia Cells |
| title_short | PF-114, a Novel Inhibitor of Bcr-Abl Chimeric Tyrosine Kinase, Attenuates Intracellular CrkL Phosphorylation and Kills Chronic Myeloid Leukemia Cells |
| title_sort | pf 114 a novel inhibitor of bcr abl chimeric tyrosine kinase attenuates intracellular crkl phosphorylation and kills chronic myeloid leukemia cells |
| topic | chronic myeloid leukemia Bcr-Abl tyrosine kinase protein phosphorylation flow cytometry cytotoxicity |
| url | http://bloodjournal.ru/en/pf-114-a-novel-inhibitor-of-bcr-abl-chimeric-tyrosine-kinase-attenuates-intracellular-crkl-phosphorylation-and-kills-chronic-myeloid-leukemia-cells/ |
| work_keys_str_mv | AT eskolotova pf114anovelinhibitorofbcrablchimerictyrosinekinaseattenuatesintracellularcrklphosphorylationandkillschronicmyeloidleukemiacells AT vvtatarskii pf114anovelinhibitorofbcrablchimerictyrosinekinaseattenuatesintracellularcrklphosphorylationandkillschronicmyeloidleukemiacells AT aazeifman pf114anovelinhibitorofbcrablchimerictyrosinekinaseattenuatesintracellularcrklphosphorylationandkillschronicmyeloidleukemiacells AT ovstroganov pf114anovelinhibitorofbcrablchimerictyrosinekinaseattenuatesintracellularcrklphosphorylationandkillschronicmyeloidleukemiacells AT vsstroilov pf114anovelinhibitorofbcrablchimerictyrosinekinaseattenuatesintracellularcrklphosphorylationandkillschronicmyeloidleukemiacells AT iyutitov pf114anovelinhibitorofbcrablchimerictyrosinekinaseattenuatesintracellularcrklphosphorylationandkillschronicmyeloidleukemiacells AT fnnovikov pf114anovelinhibitorofbcrablchimerictyrosinekinaseattenuatesintracellularcrklphosphorylationandkillschronicmyeloidleukemiacells AT aakalinina pf114anovelinhibitorofbcrablchimerictyrosinekinaseattenuatesintracellularcrklphosphorylationandkillschronicmyeloidleukemiacells AT ggchilov pf114anovelinhibitorofbcrablchimerictyrosinekinaseattenuatesintracellularcrklphosphorylationandkillschronicmyeloidleukemiacells AT aashtil pf114anovelinhibitorofbcrablchimerictyrosinekinaseattenuatesintracellularcrklphosphorylationandkillschronicmyeloidleukemiacells |